Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma

British Journal of Haematology

Volumn 161, Issue 4, 2013, Pages 499-507

  Vandyke, Kate ^a,c   Chow, Annie W S ^a   Williams, Sharon A ^a   To, Luen B ^b   Zannettino, Andrew C W ^a,c  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b SA Pathology ^*  (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Multiple myeloma; N cadherin; Prognostic marker, novel therapeutic target, ISS

Indexed keywords

CD38 ANTIGEN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; SYNDECAN 1;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MARKER GENE; MULTIPLE MYELOMA; NERVE CELL ADHESION MOLECULE GENE; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMA CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876808009     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12280     Document Type: Article

References (39)

1. Beasley, G.M., McMahon, N., Sanders, G., Augustine, C.K., Selim, M.A., Peterson, B., Norris, R., Peters, W.P., Ross, M.I. & Tyler, D.S. (2009) A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer, 115, 4766-4774.
2. Beasley, G.M., Riboh, J.C., Augustine, C.K., Zager, J.S., Hochwald, S.N., Grobmyer, S.R., Peterson, B., Royal, R., Ross, M.I. & Tyler, D.S. (2011) Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. Journal of Clinical Oncology, 29, 1210-1215.
3. Billadeau, D., van Ness, B., Kimlinger, T., Kyle, R.A., Therneau, T.M., Greipp, P.R. & Witzig, T.E. (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood, 88, 289-296.
4. Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q.L., Chen, C.I., Reece, D., Chun, K. & Keith Stewart, A. (2004) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology, 125, 64-68.
5. Chang, H., Qi, C., Yi, Q.L., Reece, D. & Stewart, A.K. (2005a) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood, 105, 358-360.
6. Chang, H., Qi, X.Y., Samiee, S., Yi, Q.L., Chen, C., Trudel, S., Mikhael, J., Reece, D. & Stewart, A.K. (2005b) Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone marrow transplantation, 36, 793-796.
7. Derycke, L., de Wever, O., Stove, V., Vanhoecke, B., Delanghe, J., Depypere, H. & Bracke, M. (2006) Soluble N-cadherin in human biological fluids. International Journal of Cancer, 119, 2895-2900.
8. Diamond, P., Labrinidis, A., Martin, S.K., Farrugia, A.N., Gronthos, S., To, L.B., Fujii, N., O'Loughlin, P.D., Evdokiou, A. & Zannettino, A.C.W. (2009) Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24, 1150-1161.
9. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
10. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., van Ness, B., van Wier, S.A., Henderson, K.J., Bailey, R.J. & Greipp, P.R. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
11. Fonseca, R., van Wier, S.A., Chng, W.J., Ketterling, R., Lacy, M.Q., Dispenzieri, A., Bergsagel, P.L., Rajkumar, S.V., Greipp, P.R., Litzow, M.R., Price-Troska, T., Henderson, K.J., Ahmann, G.J. & Gertz, M.A. (2006) Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia, 20, 2034-2040.
12. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Greipp, P.R., Litzow, M.R., Henderson, K.J., van Wier, S.A., Ahmann, G.J. & Fonseca, R. (2005) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood, 106, 2837-2840.
13. Gravdal, K., Halvorsen, O.J., Haukaas, S.A. & Akslen, L.A. (2007) A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Research, 13, 7003-7011.
14. Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412-3420.
15. Groen, R.W., de Rooij, M.F., Kocemba, K.A., Reijmers, R.M., de Haan-Kramer, A., Overdijk, M.B., Aalders, L., Rozemuller, H., Martens, A.C., Bergsagel, P.L., Kersten, M.J., Pals, S.T. & Spaargaren, M. (2011) N-cadherin-mediated adhesion of multiple myeloma cells inhibits osteoblast differentiation. Haematologica, 96, 1653-1661.
16. Hanamura, I., Stewart, J.P., Huang, Y., Zhan, F., Santra, M., Sawyer, J.R., Hollmig, K., Zangarri, M., Pineda-Roman, M., van Rhee, F., Cavallo, F., Burington, B., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, Jr, J.D. (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood, 108, 1724-1732.
17. Hazan, R.B., Kang, L., Whooley, B.P. & Borgen, P.I. (1997) N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhesion and Communication, 4, 399-411.
18. Hazan, R.B., Phillips, G.R., Qiao, R.F., Norton, L. & Aaronson, S.A. (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. Journal of Cell Biology, 148, 779-790.
19. Hideshima, T., Bergsagel, P.L., Kuehl, W.M. & Anderson, K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607-618.
20. Hulit, J., Suyama, K., Chung, S., Keren, R., Agiostratidou, G., Shan, W., Dong, X., Williams, T.M., Lisanti, M.P., Knudsen, K. & Hazan, R.B. (2007) N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Research, 67, 3106-3116.
21. Islam, S., Carey, T.E., Wolf, G.T., Wheelock, M.J. & Johnson, K.R. (1996) Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. Journal of Cell Biology, 135, 1643-1654.
22. Kastritis, E., Zervas, K., Symeonidis, A., Terpos, E., Delimbassi, S., Anagnostopoulos, N., Michali, E., Zomas, A., Katodritou, E., Gika, D., Pouli, A., Christoulas, D., Roussou, M., Kartasis, Z., Economopoulos, T. & Dimopoulos, M.A. (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia, 23, 1152-1157.
23. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
24. Lascombe, I., Clairotte, A., Fauconnet, S., Bernardini, S., Wallerand, H., Kantelip, B. & Bittard, H. (2006) N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clinical Cancer Research, 12, 2780-2787.
25. Li, G., Satyamoorthy, K. & Herlyn, M. (2001) N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Research, 61, 3819-3825.
26. Mariotti, A., Perotti, A., Sessa, C. & Ruegg, C. (2007) N-cadherin as a therapeutic target in cancer. Expert Opinion on Investigational Drugs, 16, 451-465.
27. Nagi, C., Guttman, M., Jaffer, S., Qiao, R., Keren, R., Triana, A., Li, M., Godbold, J., Bleiweiss, I.J. & Hazan, R.B. (2005) N-cadherin expression in breast cancer: correlation with an aggressive histologic variant-invasive micropapillary carcinoma. Breast Cancer Research and Treatment, 94, 225-235.
28. Nieman, M.T., Prudoff, R.S., Johnson, K.R. & Wheelock, M.J. (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. Journal of Cell Biology, 147, 631-644.
29. Nowakowski, G.S., Witzig, T.E., Dingli, D., Tracz, M.J., Gertz, M.A., Lacy, M.Q., Lust, J.A., Dispenzieri, A., Greipp, P.R., Kyle, R.A. & Rajkumar, S.V. (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 106, 2276-2279.
30. Perotti, A., Sessa, C., Mancuso, A., Noberasco, C., Cresta, S., Locatelli, A., Carcangiu, M.L., Passera, K., Braghetti, A., Scaramuzza, D., Zanaboni, F., Fasolo, A., Capri, G., Miani, M., Peters, W.P. & Gianni, L. (2009) Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Annals of Oncology, 20, 741-745.
31. Qi, J., Chen, N., Wang, J. & Siu, C.H. (2005) Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Molecular Biology of the Cell, 16, 4386-4397.
32. Rajkumar, S.V. & Kyle, R.A. (2005) Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings, 80, 1371-1382.
33. Ross, F.M., Chiecchio, L., Dagrada, G., Protheroe, R.K., Stockley, D.M., Harrison, C.J., Cross, N.C., Szubert, A.J., Drayson, M.T. & Morgan, G.J. (2010) The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica, 95, 1221-1225.
34. Sfiridaki, A., Miyakis, S., Tsirakis, G., Alegakis, A., Passam, A.M., Kandidaki, E., Margioris, A.N. & Alexandrakis, M.G. (2005) Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clinical Chemistry and Laboratory Medicine, 43, 934-938.
35. Smadja, N.V., Bastard, C., Brigaudeau, C., Leroux, D. & Fruchart, C. (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98, 2229-2238.
36. Stewart, D.J., Jonker, D.J., Goel, R., Goss, G., Maroun, J.A., Cripps, C.M., Wells, J., Wargin, W., Malik, R.K. & Peters, W.P. (2006) Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression. Journal of Clinical Oncology, 24, 3016.
37. Stewart, A.K., Bergsagel, P.L., Greipp, P.R., Dispenzieri, A., Gertz, M.A., Hayman, S.R., Kumar, S., Lacy, M.Q., Lust, J.A., Russell, S.J., Witzig, T.E., Zeldenrust, S.R., Dingli, D., Reeder, C.B., Roy, V., Kyle, R.A., Rajkumar, S.V. & Fonseca, R. (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 21, 529-534.
38. Tomita, K., van Bokhoven, A., van Leenders, G.J., Ruijter, E.T., Jansen, C.F., Bussemakers, M.J. & Schalken, J.A. (2000) Cadherin switching in human prostate cancer progression. Cancer Research, 60, 3650-3654.
39. Zannettino, A.C.W., Farrugia, A.N., Kortesidis, A., Manavis, J., To, L.B., Martin, S.K., Diamond, P., Tamamura, H., Lapidot, T., Fujii, N. & Gronthos, S. (2005) Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65, 1700-1709.